Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Core Insights - Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant and difficult-to-treat bacterial infections [1][3] - The company is advancing a broad pipeline of natural and synthetic phage candidates targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus [3] Company Overview - Armata Pharmaceuticals utilizes proprietary bacteriophage-based technology for drug development, which includes in-house phage specific cGMP manufacturing [3] - The CEO, Dr. Deborah Birx, is scheduled to present at the 5th Annual Phage Futures Annual Meeting on November 19, 2024, in Boston, MA [1]